Matt Hoffman

C++ Header Files for Stan [R package StanHeaders version 2.21.0-7]

Ben Goodrich, Matt Hoffman, Michael Betancourt, Marcus A. Brubaker et autres

Apomorphine Sublingual Film Approved for Motor Fluctuations in Parkinson Disease

Matt Hoffman

Ofatumumab Increases NEDA-3 Likelihood in MS Compared With Teriflunomide

Matt Hoffman

Novartis’s anti-CD20 monoclonal antibody has been shown to increase the odds of patients with multiple sclerosis achieving no evidence of disease activity status by more than 3-fold in the first year and more than 8-fold in the second year.

FDA Approves First Radiopharmaceutical for Imaging Tau

Matt Hoffman

For use with PET imaging, the radiopharmaceutical helps estimate density and distribution of tau, a marker of Alzheimer's disease.

Portable Neuromodulation Stimulator Device Gets Breakthrough Designation for MS

Matt Hoffman

Helius’s short-term treatment PoNS device has been approved for use in Canada, and is intended to be used alongside physical therapy for gait deficit due to mild and moderate symptoms of MS.

Celecoxib Oral Solution Approved for Acute Migraine

Matt Hoffman

The COX-2 inhibitor was OK’d for the treatment of acute migraine in adults with or without aura more than 20 years after the drug's initial approval for pain indications.

Rituximab May Be More Effective in Early-Onset Myasthenia Gravis

Matt Hoffman

This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.

Real-World Dravet Syndrome Data Suggest Fenfluramine Provides Benefit

Matt Hoffman

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Acute Migraine Agent Rimegepant Available Via Cove Telemedicine Platform

Matt Hoffman

Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions.

Positive Phase 2 Results for Edasalonexant in DMD Support Phase 3 Study

Matt Hoffman

Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.

Rimegepant FDA-Approved for Acute Migraine Treatment

Matt Hoffman

Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.

Eptinezumab Approved for Migraine Prevention

Matt Hoffman

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.